Quantinuum Inc. (QNT) · Nov 5, 2026 · Earnings
Beat — Revenue $9.05M vs ~$8.15M consensus
Quantinuum’s Q3 earnings beat the revenue consensus and raised its 2026 outlook, but losses and cash burn remain substantial.
Quantinuum is an early commercial-stage, full-stack quantum company trying to turn trapped-ion hardware, cloud access and its Nexus software platform into recurring customer demand while funding the long path to fault-tolerant systems such as Sol and Apollo. The prior public-company baseline was a 2026 revenue target of $28M-$32M, alongside a business still spending heavily on R&D and not yet near profitability.
The quarter cleared the revenue bar, but not with a clean profitability profile. Revenue reached $9.05M, about 11% above the published consensus of roughly $8.15M, and the company said its 2026 revenue outlook was raised. However, adjusted EBITDA loss widened to $80.5M from $45.3M a year earlier, while nine-month operating cash burn reached $229.9M. The filing does not provide the revised full-year revenue range, so the size of the guidance increase cannot be measured precisely. 〔0〕
| Q3 2026 | Q3 2025 | Consensus / comparison | |
|---|---|---|---|
| Revenue (Income Statement) | $9.05M (+233%) | $2.72M | ~$8.15M |
| Adjusted gross margin (Adjusted Gross Profit) | 74.6% | 66.1% | |
| Adjusted EBITDA (Non-GAAP reconciliation) | ($80.5M) | ($45.3M) | |
| Net cash used in operating activities (Cash Flow statement) | ($229.9M) | ($96.9M) | |
| Cash and cash equivalents (Balance Sheet) | $1.94B | $762.6M |
The operating story is advancing faster than the financial scale. Nexus adoption rose nearly 20% quarter over quarter to 215 organizations, while the company added a new hyperscaler agreement, expanded its Oracle relationship and signed another top-five pharmaceutical customer. Those are useful signs that the platform is moving beyond laboratory demonstrations toward broader enterprise distribution, but the revenue base remains small and contract timing still makes quarterly results volatile.
The technical milestones strengthen the core investment narrative, but remain execution claims rather than commercial proof. Quantinuum reported 99.9995% logical fidelity on Helios and kept Sol on track for the second half of 2027, reinforcing its stated path toward universal fault tolerance. These developments are meaningful for the technology roadmap, but the filing does not yet show that the improved performance is translating into material recurring revenue or lower cash consumption.
Bottom line: Quantinuum delivered a modest earnings beat and stronger commercial and technical indicators, but the company is still a high-burn development business. The quarter improves the execution narrative without changing the fundamental need to convert technical leadership into much larger customer revenue.
December Nexus release
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!